Of the &data_1_Int; subjects enrolled and &row_1_1; 15 subjects completed the study, receiving 7 &row_1_1; infusions of daratumumab.----Analysis set: all treated||Total||32||Table 4:	Subject Disposition; All Treated Analysis Set (Study GEN501 Part 1)----Of the 32 subjects enrolled and treated, 15 subjects completed the study, receiving 7 full infusions of daratumumab.
In Part 1, &data_1_Int; subjects (97%) experienced &row_1_1;----Any TEAE||Total||31 (96.9%)||Table 8:	Overview of Treatment-emergent Adverse Events; All Treated Analysis Set  (Study GEN501 Part 1)----In Part 1, 31 subjects (97%) experienced TEAEs.
&data_1_Int; subjects (16%) having &row_1_1; related to study drug.----Any serious TEAE|Drug-related||Total||5 (15.6%)||Table 8:	Overview of Treatment-emergent Adverse Events; All Treated Analysis Set  (Study GEN501 Part 1)----5 subjects (16%) having serious TEAEs related to study drug.
In &row_1_1; All-Treated Part 1 population, &data_1_Int; &row_1_1; (97%) experienced a &row_1_1;----Total no. subjects with TEAEs||Total||31 (96.9%)||Table 9:	Most Common (at least 10%) Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set  (Study GEN501 Part 1)----In the All-Treated Part 1 population, 31 subjects (97%) experienced a TEAE.
&row_1_1; 12 presents infusion-related reactions for subjects in the 8 mg/kg and 16 mg/kg &row_1_1; groups, as &row_1_1; as for the &data_1_Int; subjects across &row_1_1; dose groups who &column_1_2; included in the All-Treated Part 1 population.----Analysis set: all treated||Total|Any Grade||32||Table 12:	Infusion Related Reactions by System Organ Class, Preferred Term and Toxicity Grade; All Treated Analysis Set  (Study GEN501 Part 1)  (8 mg/kg, 16 mg/kg, and Total)----Table 12 presents infusion-related reactions for subjects in the 8 mg/kg and 16 mg/kg treatment groups, as well as for the 32 subjects across all dose groups who are included in the All-Treated Part 1 population.
&row_1_1; &data_1_Int; subjects in the &column_1_1; group discontinued &row_1_1; with daratumumab because of progressive disease (Table 21).----Analysis set: all treated||8 mg/kg - Cohort|Total||30||Table 21:	Subject Disposition - Treatment; All Treated Analysis Set (Study GEN501 Part 2)----All 30 subjects in the 8 mg/kg group discontinued treatment with daratumumab because of progressive disease (Table 21).
&row_1_2; majority of subjects were &row_1_2; (47 subjects; 65%); median &row_1_1; was 61 years.----Race, n (%)|White||Total||47 (65.3%)||Table 22:	Demographics; All Treated Analysis Set (Study GEN501 Part 2)----The majority of subjects were white (47 subjects; 65%); median age was 61 years.
Most subjects (51; 71%) had a baseline &row_1_1; performance &row_1_1; of Grade 1.----ECOG Score, n (%)|1||Total||51 (70.8%)||Table 22:	Demographics; All Treated Analysis Set (Study GEN501 Part 2)----Most subjects (51; 71%) had a baseline ECOG performance score of Grade 1.
The majority &row_1_1; subjects (50; 69%) received more than &row_1_3; &row_1_1;----Number of lines of prior therapy, n (%)|N|> 3 Lines||Total||50 (69.4%)||Table 23:	Baseline Disease Characteristics; All Treated Analysis Set (Study GEN501 Part 2)----The majority of subjects (50; 69%) received more than 3 lines of prior therapy.
All subjects (100%) received &row_1_1; treatment with bortezomib and &data_1_Int; subjects (19%) received &row_1_1; treatment with &row_1_2;----Prior PI|Carfilzomib||16 mg/kg|Total||8 (19.0%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----All subjects (100%) received prior treatment with bortezomib and 8 subjects (19%) received prior treatment with carfilzomib.
&data_1_Int; subjects (67%) received &row_1_1; &row_1_2; therapy.----Prior IMiD|Thalidomide||8 mg/kg|Total||20 (66.7%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----20 subjects (67%) received prior thalidomide therapy.
&data_1_Int; subjects (30%) had &row_1_1; SCT.----Prior Allogeneic Stem Cell Transplant||8 mg/kg|Total||9 (30.0%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----9 subjects (30%) had prior allogenic SCT.
Additionally,5 subjects (12%) were &row_1_1; bortezomib+lenalidomide+carfilzomib+pomalidomide.----Refractory toa|BORT+LEN+CARF+POM||16 mg/kg - Cohort||5 (11.9%)||Table 25:	Refractory Status to Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----Additionally,5 subjects (12%) were refractory to bortezomib+lenalidomide+carfilzomib+pomalidomide.
&data_1_Int; subjects (7%) were &row_1_1; for &row_1_3; &row_1_1; &row_1_2; (Table 28).----Duration of treatment (months)|Range|≥ 12 months||16 mg/kg||3 (7.1%)||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)----3 subjects (7%) were treated for 12 months or longer (Table 28).
In &row_1_1; &column_1_1; group, most commonly reported TEAEs &row_1_1; upper &row_1_2; tract infection (27%).----MedDRA system organ class/Preferred term|Respiratory, thoracic and mediastinal disorders|Dyspnoea||8 mg/kg|Any Grade||8 (26.7%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)----In the 8 mg/kg group, most commonly reported TEAEs were upper respiratory tract infection (27%).
&row_1_3; (5 subjects; 7%) &row_1_1; most common Grade 3/4 TEAEs.----MedDRA system organ class / Preferred term|Infections And Infestations|Pneumonia||Total||5 (6.9%)||Table 31:	Grade 3 or 4 Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)----Pneumonia (5 subjects; 7%) were the most common Grade 3/4 TEAEs.
&row_1_1; &data_1_Int; &row_1_1; IRRs across &row_1_1; combined 16 mg/kg and 8 mg/kg groups.----Total number of subjects with event of infusion related reactions||Total|Total||51||Table 36:	Time to Onset of Infusion Related Reactions; All Treated Analysis Set (Study GEN501 Part 2)----Of the 51 subjects with IRRs across the combined 16 mg/kg and 8 mg/kg groups.
For subjects in the &column_1_1; group, ORR was 10% (3 of 30 subjects; 95% CI: 2%; 27%).----Overall response (sCR+CR+VGPR+PR)||8 mg/kg|n (%)||3 (10.0%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----For subjects in the 8 mg/kg group, ORR was 10% (3 of 30 subjects; 95% CI: 2%; 27%).
&data_1_Int; subjects (26%) achieved &row_1_2;----Best response|Partial response (PR)||16 mg/kg - Cohort|Total|n (%)||11 (26.2%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----11 subjects (26%) achieved PRs.
&data_1_Int; subjects (10%) have an &row_1_2;----Best response|Minimal response (MR)||16 mg/kg - Cohort|Total|n (%)||4 (9.5%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----4 subjects (10%) have an MR.
In addition, &data_1_Int; subjects (47%) had &row_1_2;----Best response|Stable disease (SD)||8 mg/kg|n (%)||14 (46.7%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----In addition, 14 subjects (47%) had stable disease.
&data_1_Int; events (73%) were &row_1_2; in the 16 &column_1_1;----Overall survival (months)|Number of censored (%)||8 mg/kg||22 (73.3%)||Table 51:	Summary of Overall Survival; All Treated Analysis Set (Study GEN501 Part 2)----22 events (73%) were censored in the 16 mg/kg.
&data_1_Int; subjects in the &column_1_1; treatment regimen(Table 3).----Analysis set: safety||D- VTd||11||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----11 subjects in the VTd treatment regimen(Table 3).
The &data_1_Int; (33%) &row_1_1; in the &column_1_1; &row_1_1; regimen &row_1_1; study &row_1_1; for elective ASCT.----Subjects who discontinued treatment||DVd||2 (33.3%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----The 2 (33%) subjects in the Vd treatment regimen discontinued study treatment for elective ASCT.
The most commonly reported SAE was &row_1_3; (3 subjects; 6%).----System organ class/preferred term|Infections And Infestations|Pneumonia||Total||3 (6.1%)||Table 9:	Number of Subjects With 1 or More Treatment-emergent Serious Adverse Events by MedDRA System-organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY1001)----The most commonly reported SAE was pneumonia (3 subjects; 6%).
&row_1_1; were &row_1_1; in &data_1_Int; (49%) &row_1_1; during &row_1_1; study.----Total number of subjects with infusion related reactions||Total||24 (49.0%)||Table 10:	Number of Subjects With 1 or More Treatment-emergent Infusion Related Reactions by MedDRA System-organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY1001)----Infusion related reactions were reported in 24 (49%) subjects during the study.
&data_1_Int; subjects (3%) achieved VGPR or better with a &row_1_1; CR.----Stringent complete response (sCR), n (%)||16 mg/kg|Result||3 (2.8%)||Table 2	Efficacy Summary based on IRC Assessment; All Treated Analysis Set (Study 54767414MMY2002)----3 subjects (3%) achieved VGPR or better with a stringent CR.
The &row_1_1; was &data_1_Float; &row_1_1;----Median a duration of response (months)||16 mg/kg|Result||7.4||Table 2	Efficacy Summary based on IRC Assessment; All Treated Analysis Set (Study 54767414MMY2002)----The median duration of response was 7.4 months.
Study MMY2002 and Study GEN501 Part 2 are both single arm, open &row_1_1; studies in which subjects with relapsed and refractory multiple myeloma were administered &column_1_1; daratumumab (n=42 in Study GEN501 Part 2).----Analysis set: all treated||16 mg/kg|Result||42||Table 3	Efficacy Summary based on Algorithm Assessment; All Treated Analysis Set (Study 54767414GEN501)----Study MMY2002 and Study GEN501 Part 2 are both single arm, open label studies in which subjects with relapsed and refractory multiple myeloma were administered 16 mg/kg daratumumab (n=42 in Study GEN501 Part 2).
